PHARMACEUTICAL COMPOSITION FOR COLON CANCER TREATMENT OR METASTASIS SUPPRESSION, COMPRISING CADHERIN-11 PROTEIN EXPRESSION OR ACTION SUPPRESSING AGENT

WIPO Patent Application WO/2013/191445

A1

In the present invention, it has been confirmed that cadherin-11 is overexpressed in colon cancer cell lines, while the expression of cadherin-11 is disrupted by siRNA with the result that cancer cell infiltration and cell motility are reduced and epithelial-mesenchymal cells (epithelial-mesenchymal transition, EMT) are suppressed, and cell signalling is disrupted. It has also been confirmed that, with cadherin-11, expression is induced directly by means of the EMT-inducing transcription factor ZEB2 in colon cancer, liver cancer and gastric cancer cell lines, and thus cadherin-11 can be used to advantage as a pharmaceutical composition for treating or suppressing metastasis of colon cancer, liver cancer and gastric cancer.

KIM SEMI (KR)
LEE YUNHEE (KR)
NAM EUN-HEE (KR)

PCT/KR2013/005367

December 27, 2013

June 18, 2013

Click for automatic bibliography generation  

KOREA RES INST OF BIOSCIENCE (KR)

A61K48/00; A61K31/7088; A61K31/7105; A61K39/395

US20120128693A1	2012-05-24
US7972846B2	2011-07-05
US20040248220A1	2004-12-09

KAHLERT, C. ET AL.: "Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro", CLINICAL CANCER RESEARCH, vol. 17, no. 24, 2011, pages 7654 - 7663
SHIBATA, T. ET AL.: "Simultaneous expression of cadherin-11 in signet-ring cell carcinoma and stromal cells of diffuse-type gastric cancer", CANCER LETTERS, vol. 99, 1996, pages 147 - 153

LEE, Won-Hee (642-16Yoksam-dong,Kangnam-ku, Seoul 135-080, KR)

View/Download PDF      PDF Help

Previous Patent: METHOD FOR COOPERATIVE SIGNAL TRANSMITTING IN MULTI-CELL COOPERATIVE COMMUNICATION SYSTEM

Next Patent: SYSTEM AND METHOD FOR ACCUMULATING COUPONS BY USING HIGH FREQUENCY